- Trials with a EudraCT protocol (25)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
25 result(s) found for: Test statistic.
Displaying page 1 of 2.
EudraCT Number: 2009-011042-26 | Sponsor Protocol Number: V 1.01 | Start Date*: 2011-09-08 |
Sponsor Name:Medizinische Universität Wien, Univ.Klinik f.Neurologie | ||
Full Title: Botulinumtoxin type B for plantar hyperhidrosis: a randomised controlled trial | ||
Medical condition: plantar hyperhidrosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-002511-83 | Sponsor Protocol Number: TTP889-201 | Start Date*: 2005-01-03 | |||||||||||
Sponsor Name:TransTech Pharma | |||||||||||||
Full Title: A Multi-Center, Placebo-Controlled Evaluation of the Safety and Efficacy of Three Weeks Extended VTE Prophylaxis with Daily Oral Doses of TTP889 After One Week of Standard Prophylactic Treatment Fo... | |||||||||||||
Medical condition: Antithrombotic in patients at risk for venous thromboembolism | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) CZ (Completed) SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011887-12 | Sponsor Protocol Number: ADHS_Koenig | Start Date*: 2009-10-14 |
Sponsor Name:Praxis Prof. Koenig | ||
Full Title: Evaluation of ADHD from childhood to adolescence- impact of medical treatment on autonomic nervous system parameters | ||
Medical condition: ADHD is a neurobehavioral developmental disorder which affects about 5% of children. In our clinical trial designed we would like to examine whether medical treatment with stimulants has an influen... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-005169-39 | Sponsor Protocol Number: D9914C00002 | Start Date*: 2005-08-11 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A single-blind single arm study to validate the Reflux Disease Questionnaire (RDQ) for the diagnosis of reflux disease in primary care in patients treated with esomeprazole 40 mg o.d. | ||
Medical condition: Symptoms from the upper gastrointestinal tract | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) GB (Completed) DE (Completed) DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-000958-56 | Sponsor Protocol Number: 2019/375 | Start Date*: 2019-08-16 |
Sponsor Name:Helse Fonna | ||
Full Title: “Haemodynamic stability during induction of general anesthesia with propofol and remifentanil: A randomized, controlled, double-blind study comparing low vs high propofol doses.” | ||
Medical condition: In daily clinical work we observe a hypotensive effect and a reduction in HR when induction of general anesthesia is performed using propofol and remifentanil. It is difficult to differentiate the ... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: NO (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-001999-20 | Sponsor Protocol Number: RD.03.SPR.40027 | Start Date*: 2006-10-10 | |||||||||||
Sponsor Name:Galderma Research & Development SNC | |||||||||||||
Full Title: ASSESSMENT OF THE EFFICACY AND SAFETY OF THREE CONCENTRATIONS: 1%, 0.3%, 0.1% OF CD5024 CREAM ONCE DAILY AND CD5024 1% CREAM TWICE DAILY, VERSUS ITS VEHICLE AND VERSUS METRONIDAZOLE 0.75% CREAM (RO... | |||||||||||||
Medical condition: Patients with papulo-pustular rosacea | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002437-39 | Sponsor Protocol Number: SPI-103 | Start Date*: 2004-12-21 |
Sponsor Name:Daiichi Asubio Pharmaceuticals Inc. | ||
Full Title: A Phase IIb Randomized, Double-Blind, Placebo-Controlled, Group-Sequential, Multicenter, Dose Finding Study of the Safety and Efficacy of SUN N4057 (Piclozotan)Administered for 72 Hours by Continuo... | ||
Medical condition: Treatment of acute stroke. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) ES (Completed) BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-000302-12 | Sponsor Protocol Number: BUC-CLIN-303 | Start Date*: 2016-07-13 | |||||||||||
Sponsor Name:ARCA biopharma, Inc. | |||||||||||||
Full Title: GENETIC-AF – A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients with Heart Failure | |||||||||||||
Medical condition: Atrial Fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) NL (Completed) PL (Completed) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002066-57 | Sponsor Protocol Number: 3151A6-2000 | Start Date*: 2015-04-03 |
Sponsor Name:Wyeth Research | ||
Full Title: Multicenter, Open-Label, Safety, Tolerability, and Pharmacokinetic Study to Evaluate Single Ascending Doses and Subsequent Short-Term Administration of Fixed Doses of Desvenlafaxine Succinate Susta... | ||
Medical condition: Major Depressive Disorder | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-005623-27 | Sponsor Protocol Number: RM-131-009 | Start Date*: 2015-04-08 | |||||||||||
Sponsor Name:Rhythm Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients with Vomiting Symptoms and Moderate to Severe Diabetic Gastropa... | |||||||||||||
Medical condition: Vomiting symptoms in patient with moderate to severe diabetic gastroparesis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) GB (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005442-20 | Sponsor Protocol Number: E2020-G000-334 | Start Date*: 2008-09-04 |
Sponsor Name:Eisai Limited | ||
Full Title: Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children with Attention Impairment Following Cancer Treatment | ||
Medical condition: Attention impairment after cancer treatment | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) BE (Completed) ES (Completed) FR (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-005435-28 | Sponsor Protocol Number: E2020-G000-333 | Start Date*: 2008-09-03 |
Sponsor Name:Eisai Limited | ||
Full Title: Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children with Attention Impairment Following Cancer Treatment | ||
Medical condition: Attention impairment after cancer treatment | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) ES (Completed) NL (Completed) FR (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-002944-10 | Sponsor Protocol Number: c16174 | Start Date*: 2019-02-27 |
Sponsor Name:Memorial Sloan Kettering Cancer Center | ||
Full Title: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC) | ||
Medical condition: Patients with histological or cytological proof of Metastatic Castration-Resistant Prostate Cancer (mCRPC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: NL (Trial now transitioned) ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000063-88 | Sponsor Protocol Number: RAP-MD-31 | Start Date*: 2019-03-27 | |||||||||||
Sponsor Name:Allergan Ltd. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo- and Active- controlled, Multicenter Study of Rapastinel as Monotherapy in Major Depressive Disorder | |||||||||||||
Medical condition: Major depressive disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000199-25 | Sponsor Protocol Number: 009436 | Start Date*: 2014-04-22 |
Sponsor Name:Queen Mary, University of London | ||
Full Title: A Phase II, randomised, open-label study of Gemcitabine/Carboplatin first-line chemotherapy in combination with or without the antisense oligonucleotide Apatorsen (OGX-427) in advanced squamous cel... | ||
Medical condition: Advanced squamous cell lung cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-018791-24 | Sponsor Protocol Number: KM003EPC | Start Date*: 2011-07-04 | |||||||||||
Sponsor Name:Kliniken der Stadt Koeln gGmbH, Klinikum Merheim | |||||||||||||
Full Title: Single-center, single-armed, open-label, prospective study assessing efficacy and safety of a conversion of stable kidney allograft recipients to an Everolimus-based regimen to prevent the developm... | |||||||||||||
Medical condition: This study is designed to assess whether a conversion from a CNI-based therapy to a CNI-free therapy with Certican® in stable renal transplant patients is able to prevent the development of Chronic... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-018792-17 | Sponsor Protocol Number: KM004EIC | Start Date*: 2011-07-04 | |||||||||||
Sponsor Name:Kliniken der Stadt Koeln gGmbH, Klinikum Merheim | |||||||||||||
Full Title: Single-center, single-armed, open-label, prospective study assessing efficacy and safety of a conversion of kidney allograft recipients suffering from Chronic Allograft Nephropathy (CAN) assessed ... | |||||||||||||
Medical condition: This study is designed to assess whether a conversion from a CNI-based therapy to a CNI-free therapy with Certican® and Myfortic® in renal transplant patients with Chronic Allograft Nephropathy (CA... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005179-18 | Sponsor Protocol Number: RGH-MD-75 | Start Date*: 2012-03-12 | ||||||||||||||||
Sponsor Name:Forest Research Institute, Inc | ||||||||||||||||||
Full Title: A Double-blind, Placebo-controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy In Major Depressive Disorder. | ||||||||||||||||||
Medical condition: Major Depressive Disorder | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: FI (Completed) EE (Completed) SK (Completed) SE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-004751-38 | Sponsor Protocol Number: om 174 | Start Date*: 2004-02-11 | |||||||||||
Sponsor Name:OSPEDALE ONCOLOGICO DI BARI | |||||||||||||
Full Title: Vaccine with dendritic cells pulsed tumoral cell line or with autologue tumor in patients with kidney carcinoma | |||||||||||||
Medical condition: kidney carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001701-26 | Sponsor Protocol Number: C-III-001 | Start Date*: 2006-02-23 | |||||||||||
Sponsor Name:CESAR Central European Society for | |||||||||||||
Full Title: First- Line Treatment of Postmenopausal Patients with Endocrine Responsive Metastatic Breast Cancer. A Randomized, Multicenter Study Comparing Letrozole Combined with Standard Chemotherapy Vs Letro... | |||||||||||||
Medical condition: hormone-receptor-positive metastatic breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: AT (Completed) CZ (Prematurely Ended) HU (Prematurely Ended) SI (Prematurely Ended) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
